Trends In Insulin Therapy Acceptance In India
This article was originally published in Scrip
Executive Summary
An eight-city physician survey in India has thrown up some interesting findings on diabetes treatment approaches in the country, including that a significant percentage of physicians shift patients managed on oral therapies to insulin within three years largely because of poor glycemic control.
You may also be interested in...
Can Sanofi’s Toujeo Prickle Tresiba In India?
Sanofi has launched its next generation basal insulin, Toujeo, on the Indian market at a significantly reduced per unit price point versus Novo Nordisk’s Tresiba (insulin degludec), setting the stage for an interesting market expansion battle.
Life Sciences Scaling Adoption Of New Metaverse, AI Tools
Life sciences firms are increasingly adopting new technologies like the metaverse and piloting use cases, although a "truly 3D immersive customer experience" may be some distance away. But 2024 could see an inflection point with increasing demand for certain metaverse applications, says a senior Indegene executive.
Glenmark Divests API Company, Setting Out On Distinct Journeys
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”